STAAR Surgical Co
NASDAQ:STAA
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
26.14
52.25
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
STAAR Surgical Co
STAAR Surgical Co
Accounts Receivables
STAAR Surgical Co
Accounts Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accounts Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
STAAR Surgical Co
NASDAQ:STAA
|
Accounts Receivables
$104.5m
|
CAGR 3-Years
36%
|
CAGR 5-Years
28%
|
CAGR 10-Years
24%
|
|
|
Haemonetics Corp
NYSE:HAE
|
Accounts Receivables
$213.5m
|
CAGR 3-Years
15%
|
CAGR 5-Years
4%
|
CAGR 10-Years
4%
|
|
|
ICU Medical Inc
NASDAQ:ICUI
|
Accounts Receivables
$174m
|
CAGR 3-Years
14%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
17%
|
|
|
Align Technology Inc
NASDAQ:ALGN
|
Accounts Receivables
$1B
|
CAGR 3-Years
6%
|
CAGR 5-Years
14%
|
CAGR 10-Years
23%
|
|
|
Lantheus Holdings Inc
NASDAQ:LNTH
|
Accounts Receivables
$329.3m
|
CAGR 3-Years
73%
|
CAGR 5-Years
52%
|
CAGR 10-Years
23%
|
|
|
Merit Medical Systems Inc
NASDAQ:MMSI
|
Accounts Receivables
$189.8m
|
CAGR 3-Years
8%
|
CAGR 5-Years
6%
|
CAGR 10-Years
11%
|
|
STAAR Surgical Co
Glance View
STAAR Surgical Co. engages in the development, manufacture, production, marketing, and sale of implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The company is headquartered in Lake Forest, California and currently employs 692 full-time employees. The company is a manufacturer of lenses used worldwide in corrective or refractive surgery. The company sells its products in approximately 75 countries, with direct distribution in Japan, Germany, Spain, the United States, Canada, the United Kingdom and Singapore, with a combination of direct distribution and independent distribution in China, Korea, India, France, Benelux and Italy. Its manufacturing facility in Monrovia, California, makes the Visian implantable Collamer lens product family, including the EVO Visian ICL, preloaded silicone cataract intraocular lenses and injector systems. Its manufacturing facility in Brugg, Switzerland, operates an administrative, distribution and operational through its subsidiary, STAAR Surgical AG. The company operates administrative and distribution facilities in Japan through its subsidiary, STAAR Japan Inc.
See Also
What is STAAR Surgical Co's Accounts Receivables?
Accounts Receivables
104.5m
USD
Based on the financial report for Sep 27, 2024, STAAR Surgical Co's Accounts Receivables amounts to 104.5m USD.
What is STAAR Surgical Co's Accounts Receivables growth rate?
Accounts Receivables CAGR 10Y
24%
Over the last year, the Accounts Receivables growth was -7%. The average annual Accounts Receivables growth rates for STAAR Surgical Co have been 36% over the past three years , 28% over the past five years , and 24% over the past ten years .
You don't have any saved screeners yet
